Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Soleno Therapeutics, Inc. (NASDAQ: SLNO) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Soleno describes itself as a biopharmaceutical company focused on novel therapeutics for rare diseases, and its filings document financial results, material agreements, governance changes, and other significant events related to this business.
Investors can review current reports on Form 8-K in which Soleno announces quarterly and preliminary financial results, operating metrics for VYKAT XR (diazoxide choline) extended-release tablets, and updates on the U.S. launch of this once-daily oral treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. These filings incorporate press releases that discuss product revenue, profitability, cash balances, and other financial information.
Filings also describe capital structure and financing arrangements, including an accelerated share repurchase (ASR) Agreement with Jefferies LLC for up to $100 million of common stock and a first amendment to Soleno’s loan and security agreement with Oxford Finance LLC and other lenders. The 8-Ks outline key terms of these arrangements, such as prepayment of the purchase price, initial share delivery, and changes to loan availability.
Additional 8-Ks cover corporate governance and Board composition, such as the appointment of an independent director with extensive biopharmaceutical finance experience and the associated equity grants under the company’s equity incentive plan. Other filings provide Regulation FD disclosures on topics like investor presentations and safety-related communications, including Soleno’s description of a serious adverse event reported in the FDA’s FAERS database and its assessment of that event.
On this page, AI-powered tools can help summarize lengthy exhibits and press releases attached to Soleno’s filings, highlight key terms in material agreements, and clarify the implications of reported financial metrics, capital transactions, and governance changes for users reviewing SLNO’s regulatory history.
Soleno Therapeutics insider Patricia C. Hirano, Senior Vice President of Regulatory Affairs, executed a planned transaction under Rule 10b5-1 on June 24, 2025. The transaction involved:
- Exercise of employee stock options for 266 shares at $44.25 per share
- Immediate sale of the acquired 266 shares at $84.25 per share
- Net gain of $40 per share on the transaction
Following the transactions, Hirano holds 17,036 shares directly, some in the form of restricted stock units (RSUs). Notable adjustments include a 10,000-share reduction from an internal holdings review. The transactions were executed according to a trading plan established on September 13, 2024, demonstrating compliance with insider trading regulations.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) – Form 144 insider selling notice
The filing discloses that an affiliate—identified in the past-three-month sales table as Patricia Hirano—plans to sell 266 common shares through Morgan Stanley Smith Barney on or about 24 June 2025. At the reference price used in the form, the transaction is valued at $22,410.50. The shares were obtained the same day via a stock-option exercise; therefore no new shares will be issued and the sale represents just 0.0005 % of the 50.39 million shares outstanding.
The more material information is the history of insider sales included in the filing. In the preceding three months Ms. Hirano executed 14 separate sales totaling ≈160,097 shares for ≈$11 million in gross proceeds. The proposed 266-share sale appears to be a continuation of that pattern. No reference is made to a pre-arranged Rule 10b5-1 trading plan, although the form provides the option to disclose such a plan.
Investor takeaways:
- The imminent sale is immaterial in isolation, but the cumulative selling pace may raise questions about insider sentiment.
- No new dilution: the transaction merely transfers already-issued shares from an insider to the public market.
- No operational, earnings or strategic information is provided; the filing is limited to insider-trading disclosure.